Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer

Annals of Surgical Oncology

Volumn 21, Issue 9, 2014, Pages 2838-2844

  Watanabe, Masayuki ^a   Baba, Yoshifumi ^a   Yoshida, Naoya ^a   Ishimoto, Takatsugu ^a   Nagai, Yohei ^a   Iwatsuki, Masaaki ^a   Iwagami, Shiro ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF APPETITE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; ADJUVANT THERAPY; CANCER GRADING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REMISSION; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; TAXOIDS;

EID: 84906240154     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3684-8     Document Type: Article

References (32)

1. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359:1727-33.
2. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomized controlled phase III trial. Lancet Oncol. 2005;6:659-68. (Pubitemid 41222756)
3. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2007;25:2310-7.
4. Bedenne L, Michael P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. J Clin Oncol. 2007;25:1160-8. (Pubitemid 46640561)
5. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG Trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719-25. (Pubitemid 47372613)
6. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junction cancer. N Engl J Med. 2012;366:2074-84.
7. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-34. (Pubitemid 46291702)
8. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;11:681-92.
9. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol. 2003;21:4592-6. (Pubitemid 46594032)
10. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-74.
11. Igaki H, Kato H, Ando N, Shimada M, Shimizu H Nakamura T, Ozawa S, Yabusaki H, Aoyama N, Kurita A, Fukuda H. A randomized trial of postoperative chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus. Paper presented at; 2008 ASCO annual meeting.
12. Hoffman PC, Haraf DJ, Furguson MK, Drinkard LC, Vokes EE. Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol. 1998;9:647-51. (Pubitemid 28318198)
13. Watanabe M, Nagai Y, Kinoshita K, et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion. 2011;83:146-52.
14. Tanaka T, Fujita H, Sueyoshi S, et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory-metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy. 2007;53:449-53. (Pubitemid 350085262)
15. Sekiguchi H, Akiyama S, Fujiwara M, et al. Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus. Surg Today. 1999;29:97-101. (Pubitemid 29088853)
16. Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th edn. New York: Wiley; 2002. p 60-5.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
18. Japan Esophageal Society. Japanese classification of esophageal cancer. 10th edn. Tokyo: Kanehara; 2008.
19. Yoshida N, Watanabe M, Baba Y, et al. Influence of preoperative chemotherapy with docetaxel/cisplatin/5-fluorouracil on the occurrence of postoperative complications after esophagectomy for patients with advanced esophageal cancer. Dis Esophagus. In press.
20. Tachimori Y, Ozawa S, Fujishiro M, et al. Comprehensive registry of esophageal cancer in Japan, 2006. Esophagus. In press.
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Esophageal and esophagogastric junction cancers. Version 1.2013. http://www.nccn.org/professionals/physician-gls/pdf/esophageal.pdf. Accessed 17 April 2013.
22. Stahl M, Budach W, Meyer HJ, et al. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;21(5):v46-9.
23. Takahashi H, Arimura Y, Yamashita K, et al. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 2010;5:122-8.
24. Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80:307-13.
25. Osaka Y, Shinohara M, Hoshino S, et al. Phase II study of combined chemotherapy with docetaxel, CDDP, and 5-FU for highly advanced esophageal cancer. Anticancer Res. 2011;31:633-8.
26. Tamura S, Imano M, Takiuchi H, et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res. 2012;32:1403-8.
27. Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87:392-8.
28. Dexter SPL, Sue-Ling H, McMahon MJ, et al. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut. 2001;48:667-70. (Pubitemid 32378588)
29. Chan DS, Reid TD, Howell I, et al. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg. 2013;100:456-64.
30. Tanabe T, Kanda T, Kosugi S, et al. Extranodal spreading of esophageal squamous cell carcinoma: clinicopathological characteristics and prognostic impact. World J Surg. 2007;31:2192-8. (Pubitemid 47620222)
31. Sakai M, Suzuki S, Sano A, et al. Significance of lymph node capsular invasion in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:1911-7.
32. Toh Y, Oki E, Minami K, et al. Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7:37-43.